Purple Biotech Ltd. announced significant progress in its clinical development pipeline during the AACR Annual Meeting 2025, providing updates on its therapies CM24 and NT219, and progressing toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback